Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Delivery is still key in RNAi

This article was originally published in Scrip

Executive Summary

Many companies are actively exploring the potential of RNAi therapeutics, which aim at the "root" cause of genetic disease by silencing specific messenger RNAs and inhibiting the production of disease-causing proteins. But effective delivery of siRNAs into cells remains a major challenge. RNAi drugs by themselves are usually unable to pass through cell membranes and into the cytoplasm where they work.

Advertisement

Related Content

MiNA Pursuing The Other Side Of RNA Interference With Small Activating RNA Approach

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC012990

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel